ANTUREC Pharmaceuticals GmbH
Welcome to ANTUREC, a start-up founded by the Berdel/Schwöppe/Bizimis group. We have developed a therapeutic platform based on the human tissue factor. This fusion protein targets CD13, which is expressed on tumor vascular cells, leading to tumor vascular occlusion and tumor infarction. The lead protein tTF-NGR is currently in clinical phase III in a combination study together with trabectedin against advanced Soft Tissue Sarcomas. Since we target tumor vasculature, the approach is applicable to a variety of tumor entities.
The following animation and slides shows the unique mode of action of tTF-NGR
Vascular targeting by CD13-targeted tissue factor tTF-NGR - mechanismus of action
From design to clinical phase III in oncology – tTF-NGR and tumor infarction
Introduction to ANTUREC Pharmaceuticals
Latest news
2021 05 17 - Manufacturer´s authorization for tTF-NGR renewed
2021 11 12 - Start of phase III study (TRABTRAP) in patients with soft tissue sarcomas (dose-finding cohort, phase I/II)
2025 03 07 - Start of the main phase III part of TRABTRAP randomizing trabectedin standard of care versus trabectedin plus tTF-NGR
2025 10 21 - Publication of the results of the safety cohort of TRABTRAP at ESMO 2025, Berlin
2026 02 19 - Publication of the results of the safety cohort of TRABTRAP in the peer-reviewed journal Scientific Reports (Nature Portfolio journal)
About us
ANTUREC Pharmaceuticals GmbH was founded in 2020 by a team of scientists, clinical oncologists and a private investor. The company is located in Frankfurt, all scientific and clinical developments are coordinated in the beautiful city of Münster in Germany.
Vascular targeting
For more than 20 years Wolfgang Berdel and Christian Schwöppe with a research team in the University of Münster are studying new pathways of vascular targeting in anti-vascular cancer therapy.
Publications
The publications on the preclinical and clinical development of targeted vascular occlusion and tumor infarction are summarized here.
ANTUREC Pharmaceuticals GmbH
Tel.: +49 251 8356225
An der Hauptwache 7
60313 Frankfurt am Main
Mail:
hello@anturec.com